相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cutaneous melanoma
Alexander M. M. Eggermont et al.
LANCET (2014)
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
Charles G. Drake et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial
Orin Bloch et al.
NEURO-ONCOLOGY (2014)
Next-generation peptide vaccines for advanced cancer
Akira Yamada et al.
CANCER SCIENCE (2013)
Individual Patient-Specific Immunity against High-Grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein
Courtney A. Crane et al.
CLINICAL CANCER RESEARCH (2013)
International trends in the incidence of malignant melanoma 1953-2008uare recent generations at higher or lower risk?
Friederike Erdmann et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity
Beatriz M. Carreno et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Dendritic cell-based vaccines Shining the spotlight on signal 3
Gerald P. Linette et al.
ONCOIMMUNOLOGY (2013)
Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
P. F. Ferrucci et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options
Jessie Villanueva et al.
CANCER RESEARCH (2011)
Distinguishing integral and receptor-bound heat shock protein 70 (Hsp70) on the cell surface by Hsp70-specific antibodies
Gabriele Multhoff et al.
CELL STRESS & CHAPERONES (2011)
Extracellular heat shock proteins, cellular export vesicles, and the Stress Observation System: A form of communication during injury, infection, and cell damage
Antonio De Maio
CELL STRESS & CHAPERONES (2011)
The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease
Alessandra di Pietro et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification
Jun Guo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Douglas J. Schwartzentruber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma
Omar Eton et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Stepping up melanocytes to the challenge of UV exposure
Zalfa A. Abdel-Malek et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
Update on Immunologic Therapy With Anti-CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their Management
Katharina C. Kaehler et al.
SEMINARS IN ONCOLOGY (2010)
Cancer/testis (CT) antigens: Potential targets for immunotherapy
Otavia L. Caballero et al.
CANCER SCIENCE (2009)
Guidelines for the nomenclature of the human heat shock proteins
Harm H. Kampinga et al.
CELL STRESS & CHAPERONES (2009)
Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma
Nikolaus Schicher et al.
CLINICAL CANCER RESEARCH (2009)
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Heat shock proteins and immune system
Min-Fu Tsan et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2009)
Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings
E. Jonasch et al.
BRITISH JOURNAL OF CANCER (2008)
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 study group
Alessandro Testori et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
Alexander M. M. Eggermont et al.
LANCET (2008)
An adjuvant autologous therapeutic vaccine (HSPPC-96 vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentrel, open-label, randomised phase III trial
Christopher Wood et al.
LANCET (2008)
The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands
Leslie Elsner et al.
JOURNAL OF IMMUNOLOGY (2007)
Vaccine therapy for melanoma: Current status and future directions
Alicia M. Terando et al.
VACCINE (2007)
A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma
Robert G. Maki et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
Trends in melanoma epidemiology suggest three different types of melanoma
D. Lipsker et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway
Takehiro Kurotaki et al.
JOURNAL OF IMMUNOLOGY (2007)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Immunostimulatory monoclonal antibodies for cancer therapy
Ignacio Melero et al.
NATURE REVIEWS CANCER (2007)
Melanoma immunology: past, present and future
Giorgio Parmiani et al.
CURRENT OPINION IN ONCOLOGY (2007)
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group
Agop Y. Bedikian et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Somatic activation of KIT in distinct subtypes of melanoma
John A. Curtin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients
L Pilla et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Allogeneic and autologous melanoma vaccines:: Where have we been and where are we going?
VK Sondak et al.
CLINICAL CANCER RESEARCH (2006)
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma:: a randomized phase III trial of the DC study group of the DeCOG
D Schadendorf et al.
ANNALS OF ONCOLOGY (2006)
Signals required for programming effector and memory development by CD8(+) T cells
Matthew F. Mescher et al.
IMMUNOLOGICAL REVIEWS (2006)
Natural killer and NK-Like T-Cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96
L Pilla et al.
CANCER RESEARCH (2005)
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
AMM Eggermont et al.
EUROPEAN JOURNAL OF CANCER (2004)
Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells
B Berwin et al.
EMBO JOURNAL (2003)
Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells
L Rivoltini et al.
JOURNAL OF IMMUNOLOGY (2003)
The heat shock protein Gp96 binds to human neutrophils and monocytes and stimulates effector functions
MP Radsak et al.
BLOOD (2003)
Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells
E Noessner et al.
JOURNAL OF IMMUNOLOGY (2002)
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes:: Clinical and immunologic findings
F Belli et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes
T Becker et al.
JOURNAL OF CELL BIOLOGY (2002)
Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation
Y Delneste et al.
IMMUNITY (2002)
The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the toll-like receptor 2/4 pathway
RM Vabulas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Novel signal transduction pathway utilized by extracellular HSP70 -: Role of Toll-like receptor (TLR) 2 AND TLR4
A Asea et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
HSP70 as endogenous stimulus of the toll/interleukin-1 receptor signal pathway
RM Vabulas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Heat shock proteins gp96 and hsp70 activate the release of nitric oxide by APCs
NN Panjwani et al.
JOURNAL OF IMMUNOLOGY (2002)
CD40 is a cellular receptor mediating mycobacterial heat shock protein 70 stimulation of CC-chemokines
YF Wang et al.
IMMUNITY (2001)
Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice
K Sato et al.
BLOOD (2001)
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801
JM Kirkwood et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin
S Basu et al.
IMMUNITY (2001)
Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes
Y Kawakami et al.
JOURNAL OF IMMUNOLOGY (2001)
Cutting edge:: Heat shock protein gp96 induces maturation and migration of CD11c+ cells in vivo
RJ Binder et al.
JOURNAL OF IMMUNOLOGY (2000)
Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway
S Basu et al.
INTERNATIONAL IMMUNOLOGY (2000)
CD91: a receptor for heat shock protein gp96
RJ Binder et al.
NATURE IMMUNOLOGY (2000)
Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways
F Castellino et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis
H Singh-Jasuja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup Trial E1690/S9111/C9190
JM Kirkwood et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine
A Asea et al.
NATURE MEDICINE (2000)
分享论文
